



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/583,795	06/21/2006	Kiyotaka Nakano	19672-003US1 RET/PCG-9009	4422
26161 7590 06/26/2009 FISH & RICHARDSON PC P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022			EXAMINER BRISTOL, LYNN ANNE	
			ART UNIT 1643	PAPER NUMBER
			NOTIFICATION DATE 06/26/2009	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Continuation of Substance of Interview including description of the general nature of what was discussed: ODP rejection of Claims 14, 15 and 34: proposed cancelling the claims or arguing criticality of amino acid residues for binding antibodies; Claim 34 does not even identify the claimed peptide.

Objections to Claims 3, 6, 7, 14-16, 21, 22, 29, 32, 34, 36-39, 41 and 47: claims fail to identify the antigen molecule for the antibody. Discussed introducing glypican 3 into a) preamble of Claims 3, 6, and 29 to recite, for example, "an anti-glypican 3 antibody", or inserting a concluding wherein clause, for example, "wherein the antibody binds glypican 3.", and amending Claim 16 to recite "an epitope of glypican 3" in line 1.

To bring claims into condition for allowance, discussed a) cancelling withdrawn, non-elected claims 19, 20, 24-27, 43-46 and 48-53; and b) renumbering claims as 3/1, 6/2, 7/3, 14/4, 15/6, 16/5, 21/7, 22/8, 29/9, 32/10, 34/11, 36/13, 37/14, 38/15, 39/16, 41/17, 47/12. The renumbering of claims after Claim 14 would differ in the event claims 14, 15 and 34 are cancelled..